Immune-mediated disease and secondary failure to oral therapy in type 2 diabetes mellitus

Larissa Avilés-Santa, Noel Maclaren, Philip Raskin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To determine the proportion of adults with type 2 diabetes, who developed secondary failure to oral medications that had immune-mediated diabetes (IMD). Subjects and methods: One hundred and eight subjects who failed to oral therapy were screened for autoantibodies (ICA, IAA, IA-2A, and GADA 65) and HLA DR/DQ markers of IMD. Results: Mean age was 49 years and mean body mass index (BMI) was 31.5 kg/m2; 21.3% were non-Hispanic White (NHW), 32.3% Latin American (LA), and 43.2% African American (AA). Fourteen percent had one or more autoantibodies [Ab(+)]: five NHW, three LA, and seven AA. Ab(+) patients were younger (P=.03) and had lower body weight (P=.05) than Ab(-) patients. HLA markers of susceptibility for IMD were identified in 64% Ab(+) and in 43% Ab(-) (χ2, P=.46). Conclusions: These results suggest that secondary failure to oral therapy can be due to continuing IMD in obese, type 2 diabetic individuals of varying ethnic backgrounds than those who have been traditionally associated with autoimmune type 1 diabetes. Screening for markers for IMD at diagnosis could be a useful way to predict those likely to develop secondary failure to oral therapy and may assist in the selection of medical therapy.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalJournal of Diabetes and its Complications
Volume18
Issue number1
DOIs
StatePublished - Jan 2 2004

Fingerprint

Immune System Diseases
Type 2 Diabetes Mellitus
Biomarkers
Type 1 Diabetes Mellitus
African Americans
Autoantibodies
HLA-DQ Antigens
HLA-DR Antigens
Therapeutics
Body Mass Index
Body Weight

Keywords

  • Autoimmune diabetes
  • Ethnicity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Immune-mediated disease and secondary failure to oral therapy in type 2 diabetes mellitus. / Avilés-Santa, Larissa; Maclaren, Noel; Raskin, Philip.

In: Journal of Diabetes and its Complications, Vol. 18, No. 1, 02.01.2004, p. 10-17.

Research output: Contribution to journalArticle

@article{08825399845b47c8a8fbc615259b43ab,
title = "Immune-mediated disease and secondary failure to oral therapy in type 2 diabetes mellitus",
abstract = "Purpose: To determine the proportion of adults with type 2 diabetes, who developed secondary failure to oral medications that had immune-mediated diabetes (IMD). Subjects and methods: One hundred and eight subjects who failed to oral therapy were screened for autoantibodies (ICA, IAA, IA-2A, and GADA 65) and HLA DR/DQ markers of IMD. Results: Mean age was 49 years and mean body mass index (BMI) was 31.5 kg/m2; 21.3{\%} were non-Hispanic White (NHW), 32.3{\%} Latin American (LA), and 43.2{\%} African American (AA). Fourteen percent had one or more autoantibodies [Ab(+)]: five NHW, three LA, and seven AA. Ab(+) patients were younger (P=.03) and had lower body weight (P=.05) than Ab(-) patients. HLA markers of susceptibility for IMD were identified in 64{\%} Ab(+) and in 43{\%} Ab(-) (χ2, P=.46). Conclusions: These results suggest that secondary failure to oral therapy can be due to continuing IMD in obese, type 2 diabetic individuals of varying ethnic backgrounds than those who have been traditionally associated with autoimmune type 1 diabetes. Screening for markers for IMD at diagnosis could be a useful way to predict those likely to develop secondary failure to oral therapy and may assist in the selection of medical therapy.",
keywords = "Autoimmune diabetes, Ethnicity, Type 2 diabetes",
author = "Larissa Avil{\'e}s-Santa and Noel Maclaren and Philip Raskin",
year = "2004",
month = "1",
day = "2",
doi = "10.1016/S1056-8727(02)00253-2",
language = "English (US)",
volume = "18",
pages = "10--17",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Immune-mediated disease and secondary failure to oral therapy in type 2 diabetes mellitus

AU - Avilés-Santa, Larissa

AU - Maclaren, Noel

AU - Raskin, Philip

PY - 2004/1/2

Y1 - 2004/1/2

N2 - Purpose: To determine the proportion of adults with type 2 diabetes, who developed secondary failure to oral medications that had immune-mediated diabetes (IMD). Subjects and methods: One hundred and eight subjects who failed to oral therapy were screened for autoantibodies (ICA, IAA, IA-2A, and GADA 65) and HLA DR/DQ markers of IMD. Results: Mean age was 49 years and mean body mass index (BMI) was 31.5 kg/m2; 21.3% were non-Hispanic White (NHW), 32.3% Latin American (LA), and 43.2% African American (AA). Fourteen percent had one or more autoantibodies [Ab(+)]: five NHW, three LA, and seven AA. Ab(+) patients were younger (P=.03) and had lower body weight (P=.05) than Ab(-) patients. HLA markers of susceptibility for IMD were identified in 64% Ab(+) and in 43% Ab(-) (χ2, P=.46). Conclusions: These results suggest that secondary failure to oral therapy can be due to continuing IMD in obese, type 2 diabetic individuals of varying ethnic backgrounds than those who have been traditionally associated with autoimmune type 1 diabetes. Screening for markers for IMD at diagnosis could be a useful way to predict those likely to develop secondary failure to oral therapy and may assist in the selection of medical therapy.

AB - Purpose: To determine the proportion of adults with type 2 diabetes, who developed secondary failure to oral medications that had immune-mediated diabetes (IMD). Subjects and methods: One hundred and eight subjects who failed to oral therapy were screened for autoantibodies (ICA, IAA, IA-2A, and GADA 65) and HLA DR/DQ markers of IMD. Results: Mean age was 49 years and mean body mass index (BMI) was 31.5 kg/m2; 21.3% were non-Hispanic White (NHW), 32.3% Latin American (LA), and 43.2% African American (AA). Fourteen percent had one or more autoantibodies [Ab(+)]: five NHW, three LA, and seven AA. Ab(+) patients were younger (P=.03) and had lower body weight (P=.05) than Ab(-) patients. HLA markers of susceptibility for IMD were identified in 64% Ab(+) and in 43% Ab(-) (χ2, P=.46). Conclusions: These results suggest that secondary failure to oral therapy can be due to continuing IMD in obese, type 2 diabetic individuals of varying ethnic backgrounds than those who have been traditionally associated with autoimmune type 1 diabetes. Screening for markers for IMD at diagnosis could be a useful way to predict those likely to develop secondary failure to oral therapy and may assist in the selection of medical therapy.

KW - Autoimmune diabetes

KW - Ethnicity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=1542513685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542513685&partnerID=8YFLogxK

U2 - 10.1016/S1056-8727(02)00253-2

DO - 10.1016/S1056-8727(02)00253-2

M3 - Article

C2 - 15019594

AN - SCOPUS:1542513685

VL - 18

SP - 10

EP - 17

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 1

ER -